Oculis, a clinical-stage biotechnology company focused on the development of non-invasive topical treatment for back-of-the-eye diseases, announced it has successfully closed a Series B financing round of CHF 20 million. In conjunction with the financing, Oculis is re-locating its corporate headquarters to Lausanne.
Find an actor

ILMAC Lausanne 201803.10.2018

ILMAC Lausanne is the new platform for the chemical & life sciences community. The event will take place on 3 and 4...

Alcon arrive à Genève

Alcon quitte Novartis et choisi le canton de Genève pour s'installer avec une équipe de 700 personnes.
Print this page Download this page (PDF) Recommend this page to a friend

Contact us

BioAlps Association
Ch. du Pré-Fleuri 3
CH - 1228 Plan-les Ouates
+41 22 304 40 40
+41 22 304 40 70

Subscribe to our newsletter

Find us on LinkedIn